Category
All
New Technology
Service & Software
Internet & Communication
Electronics & Semiconductor
Pharma & Healthcare
Other
Energy & Power
Agriculture
Consumer Goods
Machinery & Equipment
Food & Beverages
Medical Care
Automobile & Transportation
Packaging
Chemical & Material
Medical Devices & Consumables
Category
All
Total: 2 records, 1 pages
Search For: Anti-amyloid-β Monoclonal Antibodies
Global Anti-amyloid-β Monoclonal Antibodies Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
27 Oct 2024
Pharma & Healthcare
Anti-amyloid-β Monoclonal Antibodies
Anti-amyloid-β monoclonal antibodies are a class of targeted biologic therapies designed to bind specifically to amyloid-beta peptides in the brain, which are associated with the formation of amyloid plaques in Alzheimer's disease. By targeting these plaques, these antibodies aim to facilitate their clearance from the brain, potentially slowing the progression of neurodegeneration and improving cognitive function in patients.Examples include donanemab and lecanemab, which have been developed to treat early stages of Alzheimer's.
USD3480.00
Add To Cart
Global Anti-amyloid-β Monoclonal Antibodies Supply, Demand and Key Producers, 2024-2030
27 Oct 2024
Pharma & Healthcare
Anti-amyloid-β Monoclonal Antibodies
Anti-amyloid-β monoclonal antibodies are a class of targeted biologic therapies designed to bind specifically to amyloid-beta peptides in the brain, which are associated with the formation of amyloid plaques in Alzheimer's disease. By targeting these plaques, these antibodies aim to facilitate their clearance from the brain, potentially slowing the progression of neurodegeneration and improving cognitive function in patients.Examples include donanemab and lecanemab, which have been developed to treat early stages of Alzheimer's.
USD4480.00
Add To Cart
Popular Product Keywords
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
Search For: Anti-amyloid-β Monoclonal Antibodies
Total: 2 records, 1 pages
Anti-amyloid-β monoclonal antibodies are a class of targeted biologic therapies designed to bind specifically to amyloid-beta peptides in the brain, which are associated with the formation of amyloid plaques in Alzheimer's disease. By targeting these plaques, these antibodies aim to facilitate their clearance from the brain, potentially slowing the progression of neurodegeneration and improving cognitive function in patients.Examples include donanemab and lecanemab, which have been developed to treat early stages of Alzheimer's.
USD3480.00
Add To Cart
Anti-amyloid-β monoclonal antibodies are a class of targeted biologic therapies designed to bind specifically to amyloid-beta peptides in the brain, which are associated with the formation of amyloid plaques in Alzheimer's disease. By targeting these plaques, these antibodies aim to facilitate their clearance from the brain, potentially slowing the progression of neurodegeneration and improving cognitive function in patients.Examples include donanemab and lecanemab, which have been developed to treat early stages of Alzheimer's.
USD4480.00
Add To Cart
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
-
Insight into the industry market information
-
Analyze market development needs
-
Prospects for future development
-
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>